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Phenotype-driven bioinformatic prioritization of candidate genes was applied for the 
diagnosis of rare, genetic diseases using targeted next-generation sequencing of the 
disease-associated genome. 
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Abstract 
Less than half of patients with suspected genetic disease receive a molecular diagnosis. We 
have therefore integrated next-generation sequencing, bioinformatics, and clinical data into 
an effective diagnostic workflow. We used variants in the 2741 established Mendelian 
disease genes (the disease-associated genome (DAG)) to develop a targeted enrichment 
DAG panel (7.1 Mb), which achieves a coverage of 20-fold or better for 98% of bases. 
Furthermore, we established a computational method (Phenotypic Interpretation of eXomes 
(PhenIX)) that evaluated and ranked variants based on pathogenicity and semantic similarity 
of patients’ phenotype described by Human Phenotype Ontology (HPO) terms to those of 
3991 Mendelian diseases. In computer simulations, ranking genes based on the variant 
score put the true gene in first place less than 5% of the time; PhenIX placed the correct 
gene in first place over 86% of the time. A retrospective test of PhenIX on 52 patients with 
previously identified mutations and known diagnoses, achieving a mean rank of 2.1 for the 
correct gene. In a prospective study on 40 individuals without a diagnosis, PhenIX analysis 
enabled a diagnosis in 11 cases (28%, at a mean rank of 2.4). Thus, the combination of 
targeted next generation sequencing (NGS) investigation of the DAG followed by phenotype-
driven bioinformatic analysis allows quick and effective differential diagnostics in medical 
genetics.  
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Introduction 
At the time of this writing, roughly 7,000 Mendelian diseases are recognized (1-3). Although 
these diseases are individually rare, up to 8% of the population is affected by a specific 
genetic disorder (4). Because of the vast number of diseases, many of which have a broad 
and incompletely understood phenotypic spectrum, and the high genetic heterogeneity of 
many clinical syndromes such as intellectual disability, the diagnostic process in medical 
genetics is often challenging, even for experienced and expert clinicians. The traditional 
medical genetics evaluation relies upon recognizing a characteristic pattern of signs or 
symptoms to guide targeted genetic testing for confirmation of the diagnosis, with the major 
diagnostic methods including karyotyping, array comparative genomic hybridization (CGH), 
biochemical testing, and Sanger sequencing of individual genes. However, the diagnostic 
yield remains less than 50% even after extensive workups (5), with the costs of clinical and 
molecular genetic analysis for patients whose diagnosis is not clear after the first visit 
reaching 25,000 US dollars or more (5). 
The term “diagnostic odyssey” has been used to describe the experience of patients and 
families affected by rare diseases that cannot be diagnosed; for instance, the average time 
between the onset of symptoms and the correct diagnosis is currently 14 years for patients 
with type 2 myotonic dystrophy (6). The lack of a diagnosis can mean missed opportunities 
for tailored approaches to clinical management and treatment strategies, a substantial 
burden of guilt and uncertainty for families, and the inability to make accurate statements on 
recurrence risk and prognosis, not to mention the economic costs of unnecessary diagnostic 
procedures. 
Whole-exome sequencing (WES), first used in 2010 to identify the cause of a Mendelian 
disease (7), is rapidly becoming attractive as a tool for diagnostic testing in general medical 
genetics (8). Additionally, NGS-panel, WES, and whole genome sequencing (WGS) 
approaches have been introduced for carrier screening (9) as well as in neonatal intensive 
care units (10). However, medical interpretation of WES results remains challenging, and the 
successes have for the most part been limited to single cases or small groups of patients 
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(11). Identifying the one or two causative mutations amongst the myriad of variants present 
in the WES findings of an individual has been compared to finding a needle in a haystack 
(12). A typical exome contains well over 30,000 variants when compared to the human 
reference sequence, with about 10,000 of them representing nonsynonymous amino acid 
substitutions, alterations of conserved splice site residues, or small insertions or deletions 
(13, 14). Although the community has developed numerous bioinformatic tools to filter out 
common variants and predict their pathogenicity (15, 16), each human genome harbors 
about 100 genuine loss of function variants with ~20 genes completely inactivated (17). 
Therefore, purely sequenced-based evaluation of genes in diagnostic WES typically 
identifies tens or hundreds of candidates. While this is acceptable in a research context, in 
which other strategies such as genetic linkage or comparison with a study group of 
individuals thought to have the same disease can often reduce the search space, extensive 
evaluation of long lists of candidate genes does not scale well to the diagnostic setting.  
Depth and uniformity of coverage have a major influence on the performance of targeted 
capture for next-generation sequencing. For instance, at a mean on-target read depth of 20x, 
up to 15% of heterozygous single nucleotide variants will be missed (18). Although initial 
WES studies aimed for a coverage of 20-fold, deeper coverage is needed for accurate 
detection of heterozygous variants (19), and current studies typically employ a coverage of 
50-70-fold (20, 21) or higher. This has led to debate in the community as to the relative value 
of various NGS approaches for diagnostics, with proponents of targeted panel sequencing 
(22), WES (23), and whole genome sequencing (WGS) (24).  
In this work, we explore a different approach towards the translation of NGS-based 
diagnostics into clinical diagnostics in a medical genetics clinic. We contend that WES is not 
optimal in a purely diagnostic setting, since we can currently offer a confident interpretation 
of variants only in ~2740 known Mendelian disease genes; the identification of a potentially 
pathogenic variant in a gene regarded as a good candidate because of biochemical or 
model-organism data often represents the starting point for a good research project, but is 
more likely to engender confusion in a diagnostic setting. Therefore, by enriching for genes 
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known to be associated with Mendelian disease, we shift the focus from the whole exome to 
that part of the exome/genome that is clinically interpretable in a diagnostic setting. We refer 
to this portion of our genome as the disease-associated genome (DAG). A pathogenic 
variant in one of these genes is, in principle, interpretable in the context of the presenting 
clinical phenotype and our knowledge of the diseases associated with the gene in question.  
We have previously shown that phenotypically driven genomic data fusion (25) and 
comparison of human to model organism phenotypes (26) dramatically improves the ability to 
correctly identify candidate disease-causing mutations in WES studies. Here, we use the 
Human Phenotype Ontology (HPO) and associated data to develop a computational 
procedure for differential diagnosis with the DAG panel. The HPO provides a structured, 
comprehensive and well-defined set of over 10,000 terms describing human phenotypic 
abnormalities. It provides annotations of nearly 7,300 human hereditary syndromes that yield 
computable representations of the diseases, associated disease genes, as well as the signs, 
symptoms, laboratory findings, and other phenotypic abnormalities that characterize the 
diseases (3, 27). Here, we adapt our semantic similarity approach towards differential 
diagnosis, using terms and annotations from the HPO (28), to rank candidate genes in a 
diagnostic setting. Our algorithm is freely available for academic use through the website 
http://compbio.charite.de/PhenIX/. 
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Results 
 
Here we present an approach to Mendelian disease diagnostics that involves the targeted 
sequencing of the DAG panel combined with a phenotype-driven computational analysis 
strategy (PhenIX) that ranks candidate genes on the basis of the presence of rare, predicted 
pathogenic variants and the clinical relevance of the genes with associated disease 
phenotypes.  Our algorithm first filters the variants according to rarity, target region location, 
and predicted pathogenicity. Next, the remaining candidate genes are evaluated for clinical 
relevance on the basis of the semantic similarity of the patient’s phenotypic abnormalities to 
the phenotypic spectrum of diseases associated with each candidate gene. In brief, our 
method aims to identify and rank disease genes by combining potential clinical relevance 
with deleterious variants found within those genes (see Methods section). 
 
Design and Validation of the Disease-Associated Genome Panel 
We established a comprehensive catalog of Mendelian disease genes using data from the 
Human Phenotype Ontology project (3), part of which is derived from information in the 
Online Mendelian Inheritance in Man (OMIM) (1) and Orphanet (2) resources. The HPO 
project, which was initiated in 2007, has grown to include over 10,000 terms describing 
individual phenotypic abnormalities that have been used to generate over 110,000 
annotations to over 7000 mainly Mendelian disease entries (3, 27). The data in the HPO thus 
provides a powerful curated resource for translational research by providing the means to 
capture, store, and exchange phenotypic information about human disease and has been 
used to integrate phenotypic information into computational analysis (25, 26, 28-32). We 
additionally surveyed the recent literature to obtain additional information about plausible 
candidate disease genes from recent publications describing large-scale WES studies were 
also included (8, 33-37), for a total of 2741 genes (genes and references are included in 
Table S6). 
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Since our aim was to obtain nearly complete coverage of the DAG, we designed enrichment 
probes for the DAG using SureSelect technology (38). In total 96 samples were sequenced 
(six samples per lane of an Illumina HiSeq 1500 sequencer), resulting in an average 
coverage of 361.7±81.6 reads (135.6 ±10.6 after removal of duplicates), with 98% of the 
DAG target region being covered by at least 20 reads (Figure S1; Tables S1 and S2).  
In order to estimate the advantage of the high coverage of the DAG panel with respect to 
comprehensive variant calling, we randomly sampled reads from the Binary Alignment/Map 
(BAM) files from the DAG target region (twice over each of the 96 sequenced DAG samples) 
to a target average coverage of 100-fold to simulate the coverage expected from typical 
exome sequencing. After this, the down-sampled BAM files were processed in the same way 
as the original BAM files, and the distribution of called variants was compared (Table S3). A 
substantial number of variants called from the original BAM file were not called from the files 
simulated to have exome or genome coverage, including an average of 5.2 ± 2.0 variants 
listed in the Human Gene Mutation Database (HGMD) (39).  
 
Phenotypic Interpretation of eXomes: PhenIX 
We developed a computational algorithm to filter and rank candidate genes according to 
variant rarity and pathogenicity and potential clinical relevance of the gene harboring the 
variants. As input, PhenIX requires (i) a variant call format (VCF) file representing the results 
of sequencing the DAG target region (or an exome or genome), and (ii) a list of Human 
Phenotype Ontology (HPO) terms representing the clinical features of the individual being 
sequenced. Each variant is scored on the basis of rarity and predicted pathogenicity; after 
this, all variants mapping to a given gene are combined. The genes harboring predicted 
pathogenic variants are assigned a phenotype score by using the semantic similarity 
between associated disease phenotypes and the patient’s phenotype. However, the gene is 
down-weighted if the distribution of variants in a gene is incompatible with the mode of 
inheritance of the associated disease, e.g., if a single heterozygous variant is observed in a 
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gene associated with an autosomal recessively inherited disease. Finally, a rank is 
calculated based on the combined variant and phenotype scores. 
 
To estimate the performance of our method, we conducted extensive computational 
simulations using mutation data from the HGMD. Sample datasets were simulated for a 
given disease and inheritance model by spiking with mutations from HGMD into a VCF file 
generated with the DAG panel. Appropriate HPO terms were chosen from the annotations of 
the corresponding disease. Several test scenarios were considered. The performance of the 
method was near 100% when all the HPO terms annotating the disease (e.g., Greig 
cephalopolydactyly syndrome is annotated with 44 HPO terms representing individual signs 
and symptoms of that disease). In another, more realistic, test scenario, up to five terms 
were chosen, of which two were made imprecise by exchanging them with the more general 
parent term, and two unrelated confounder (“noise”) terms were added at random. Here, the 
correct gene was ranked in first place in 86.5% of 8504 simulations, corresponding to a 32.5-
fold improvement over pure variant filtering (Figure 1, Figure S2).   
 
Retrospective analysis 
We then tested the performance of our method with the generated DAG data from 52 
individuals with a diagnosis of Mendelian disease that had been confirmed by Sanger 
sequencing (Table 1). HPO terms were entered and filtering was performed at a frequency 
threshold of 1%. The average rank of the correct gene amongst the 2741 disease genes in 
the DAG panel was 2.1. The mean rank of the autosomal recessive genes was 5, 
substantially lower than for the autosomal dominant genes (1.7). The lower rank for the 
recessive genes was partially related to results for an individual with eczematoid 
acrodermatitis enteropathica, who had a missense mutation in SLC39A4 that was correctly 
flagged as pathogenic as well as a synonymous mutation that had been shown to cause a 
splice defect. The latter mutation was not identified as deleterious by PhenIX, resulting in a 
final rank of 14 for SLC39A4.  
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Prospective analysis 
To further validate our methodology, we investigated 40 individuals who, after extensive 
clinical genetic evaluation (physical exam by medical geneticist, array CGH, and often 
targeted Sanger gene sequencing), remained without a diagnosis (clinical features 
summarized in Table 2). We designed a standard evaluation procedure in which deep 
phenotyping (40) with the selection of representative HPO terms (3, 27) was followed by 
targeted NGS of the DAG panel. Computational analysis was performed as described above 
to generate a ranked list of candidates based on the combined variant and clinical relevance 
scores. Since our computational simulations almost always placed the true disease gene in 
the top 10 candidates, we limited our evaluation to the top 20 ranked genes as well as any 
gene with a pathogenic mutation at the same nucleotide position listed in HGMD (39) or 
ClinVar (41) for each patient. Initial clinical evaluation was performed by one of the authors, 
and a short list of the most likely candidates was presented to the entire group in clinical 
rounds, where up to the best two candidate genes were chosen based on clinical experience. 
These genes were subjected to Sanger validation and cosegregation studies. If the variants 
in the selected genes cosegregated as expected and the clinical manifestations of the patient 
were sufficiently explained by a disease associated with the gene, then a positive diagnosis 
was made. Otherwise, the short list was re-examined for additional candidates (Fig 2). We 
estimate an experienced clinical geneticist would spend a total of one hour in the initial 
evaluation of the patient and decision whether to perform DAG panel sequencing and an 
additional one hour studying the list of top 20 candidates, evaluating the results of Sanger 
validation and cosegregation studies before being able to decide whether a definitive 
diagnosis can be made. 
 
By applying this procedure to 40 individuals, we identified a definitive diagnosis in eleven 
(28%) cases.  Table 2 shows a clinical summary of these cases, and Tables S4 and S5 
include a full list of HPO terms used to search in PhenIX. PhenIX analysis was performed 
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according to the flow chart in Figure 2, and the top 20 genes were inspected. Discussion at 
clinical genetics rounds flagged one (n=16 only one) or two (n=6) genes as being likely 
candidates. These genes were then subjected to Sanger validation, cosegregation studies 
and close examination. This led to definitive diagnoses being made in 11 of 40 patients 
(28%) (Table 3). 
 
Discussion 
Genomic medicine, including WES and WGS, is poised to transform clinical practice in many 
fields (42). Here, we present a phenotype-driven computational and clinical workflow for the 
efficient diagnosis of rare Mendelian diseases. Our approach uses the results of clinical 
analysis to substantially improve the ranking of candidate genes, and provides a clear 
pathway to integrate the results of bioinformatic analysis into the clinical workflow by clinical 
evaluation of phenotypic matching amongst the best candidates. 
In this work, we have shown how to use a computable representation of clinical phenotypes 
to prioritize candidate genes in diagnostic sequencing with a target panel of 2741 known 
Mendelian disease genes. Our workflow represents a tight integration of clinical and 
bioinformatic analysis (Fig. 2). Clinical expertise is required to perform deep phenotyping and 
choose representative HPO terms to describe the clinical features of the patient being 
investigated. Experience is necessary to realize whether a given phenotypic abnormality is 
likely to be characteristic of a disease or an incidental finding, e.g. a feature such as low-
grade myopia may not be related to the genetic disease being sought and adding this feature 
to PhenIX analysis may lower the score of the actual disease-causing gene. Following 
sequencing, alignment, and variant calling, PhenIX analysis is used to generate a list of the 
top 20 candidates. Additional candidates can be listed if desired. Clinical expertise is 
required to examine this list for promising candidates based on additional information from 
original publications and databases, such as OMIM. To assist with this process, the PhenIX 
webpage provide links to a number of useful resources including OMIM, the UCSC Genome 
Browser, ClinVar, and HGMD. We suggest that a presentation of the case together with a 
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description of the best PhenIX candidates at clinical genetics rounds should be performed, 
followed by validation of the most plausible candidate(s) by Sanger sequencing and 
cosegregation studies. In our experience, discussions on the differential diagnosis proceed 
quickly when organized in this fashion and fit well into a typical clinical workflow. We chose to 
limit our NGS analysis only to the sample from the affected individual, because in the 
diagnostic setting family samples (trios) may not be available initially. In addition, the cost of 
sequencing may be a factor. However, trio sequencing could easily be adapted into our 
workflow. 
On the basis of our results, we suggest that targeting all known disease genes, that is a 
DAG, rather than the whole exome or genome, is advantageous in terms of target coverage, 
cost per sample, and the ability to provide quick and accurate clinical interpretation of the 
variants. Cases that remain unsolved after PhenIX analysis of the DAG Panel can be 
considered for more time-intensive clinical research WES/WGS studies, as these 
approaches are able to search for potential mutations in previously undescribed disease 
genes.  
There are several areas in which our approach can be improved and extended. The 
phenotypic analysis based on semantic similarity depends on an annotated corpus of 
information about the phenotypic features that characterize various diseases. The 
HPO currently has over 110,000 annotations to over 7000 diseases listed in the 
Online Mendelian Inheritance in Man (3). Increasing the depth of annotation to these 
diseases would improve the performance (43). A number of challenges remain in the 
ontological modeling of certain classes of diseases and phenotypes in areas such as 
neurobehavioral abnormalities (44). The DAG panel as presented here currently 
contains baits only for protein coding genes. However, other medically relevant 
sequences of the genome could be captured in a similar way, such as enhancers of 
the sonic hedgehog gene, in which point mutations can cause characteristic skeletal 
malformations (45). Hand in hand with this, future bioinformatics research will be 
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required to confidently identify medically relevant variants in non-coding sequences 
as well as presumptive synonymous variants that actually lead to a deleterious effect 
such as defective splicing in the case of the “silent” SLC39A4 mutation mentioned 
above. Our approach concentrates on known disease genes, and is thus not 
designed or intended to  identify novel disease genes; other computational tools such 
as the Exomiser (26) and eXtasy (25) have been presented for this purpose. 
In summary, we have presented a diagnostic tool for genetics professionals that combines 
targeted enrichment and next-generation sequencing of a comprehensive panel of genes 
known to be associated with Mendelian disease; bioinformatics analysis of sequencing 
results is tightly coupled to the expertise and workflow of genetics professionals, allowing a 
complete workup of NGS results in roughly two hours per patient. A recent study on the use 
of diagnostic exome sequencing of 250 unselected, consecutive cases achieved a diagnostic 
yield of 25% (8), and another larger scale exome-based study on persons with intellectual 
disability reached a diagnostic yield of 16% (46). Although it is hard to compare the 
diagnostic yield between different studies, the results presented here are competitive, with an 
average rank of the correct gene of 2.1 in a retrospective study on representative diseases 
and a yield of 28% in prospective study with cases chosen for the fact that a diagnosis could 
not be achieved. Additionally, our method requires less sequencing than high coverage WES 
or WGS which may translate into cost benefits. Our bioinformatic and clinical workflow could 
be completed in roughly two hours per patient, and PhenIX analysis is easy to use, requiring 
only a VCF file and a list of HPO terms. Our method thus provides the means for quick and 
effective differential diagnostics in medical genetics.  
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MATERIALS AND METHODS 
Consent 
This study was approved by the Institutional Review Board of the Charité Universitätsmedizin 
Berlin. Informed written consent was obtained from adult subjects and parents of children. 
Case selection 
The control group consisted of 52 individuals with suspected genetic diagnoses seen at the 
Institute of Medical Genetics and Human Genetics of the Charité university hospital between 
2010 and 2013, and who received an etiological diagnosis based on clinical findings and the 
identification of mutations in the genes indicated in Table 1. In addition, 38 patients seen 
during this time frame who remained without an etiological diagnosis were investigated in this 
study. Patients were chosen on the basis of availability of DNA samples from parents (for 
validation of cosegregation by Sanger sequencing), consent for research, and the inability to 
identify a genetic diagnosis despite a high index of suspicion of an underlying genetic cause. 
Two additional cases were referred from external clinics and were not seen in our 
department (P6 and P10 in Table 3). 
 
Capture of the targeted disease-related genome and Next-Generation Sequencing 
A SureSelectXT Automation Custom Capture Library (Agilent) target enrichment panel was 
generated using the coordinates given in Table S6. The enrichment panel comprised all 
coding exons of 2741 genes associated with at least one Mendelian disease as well as 133 
control genes. Capture was performed according to the manufacturer’s instructions using an 
NGS Workstation Option B (Agilent) for automated library preparation starting with 3 µg DNA 
per sample. Then, sequencing of 100 bp paired-end reads was carried out on a HiSeq 1500 
(Illumina). Sequence reads were mapped to the haploid human reference genome (hg19) 
with Novoalign (Novocraft Technologies). Single nucleotide variants (SNVs) and short 
insertions and deletions (indels) were called using GATK version 2.8 (47). Variant annotation 
was performed with Jannovar (48). In total, 96 samples were sequenced on two HiSeq 1500 
flowcells. 
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PhenIX: Bioinformatic ranking of candidate genes. Ranking of candidate genes was 
performed in two steps. First, off-target and synonymous variants were removed, and the 
remaining variants were analyzed with respect to population frequency by using data from 
dbSNP (49) and from the Exome Variant Server (NHLBI GO Exome Sequencing Project 
2014, http://evs.gs.washington.edu/EVS/). For the purposes of analysis, we assumed the 
minor allele frequency of each variant to be the maximum frequency reported by dbSNP or 
that of the African American or European American populations represented in the Exome 
Variant Server. A frequency score is calculated as max�0,1− 0.13533𝑒100∗𝑓�, and variants 
with no frequency data (𝑓 = 0) were assigned a score of 1.0, and results in values between 
1.0 and 0.0 for variants with frequencies of up to 2%. Predicted pathogenicity of missense 
variants was derived from dbNSFP version 2.4 (50) using the fields for MutationTaster (16), 
polyphen-2 (15), and SIFT (51). Scores from these three prediction tools were normalized to 
be between 0.0 (benign) and 1.0 (pathogenic), and the single most pathogenic score was 
taken for each variant. For classes of variants other than missense mutations, a 
pathogenicity score was calculated as described (26). Finally, the overall variant score was 
calculated as the product of the frequency and pathogenicity score. A clinical relevance 
score was calculated using the semantic similarity between phenotypic abnormalities entered 
by the user and 2741 disease genes in our database. The phenotypic abnormalities of all 
diseases associated with a given gene were assigned to the gene, since our method ranks 
candidate genes rather than individual diseases. For instance, the FBN1 gene is mutated in 
Marfan syndrome, acromicric dysplasia, and a number of other diseases, and the phenotypic 
abnormalities of each of those diseases were assigned to FBN1. Then, the semantic 
similarity score of the Phenomizer algorithm (28) was calculated for each of the genes. The 
maximum score was set to 1.0, and the other scores were normalized accordingly. The final 
score was calculated as the average of the variant and the gene-relevance score. However, 
if the variant distribution for a gene was not compatible with the mode of inheritance of the 
associated diseases (e.g., a gene has only a single heterozygous mutation but the 
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associated disease is autosomal recessive, or the gene has only a single homozygous 
mutation but the disease is autosomal dominant), then the gene relevance score was divided 
by 2 before calculating the final score. The final score was calculated as the mean of the 
variant score and the gene relevance score. The major distinction between PhenIX and our 
previously published algorithm PHIVE, which is implemented in the Exomiser (26) is thus the 
restriction of the analysis to variants in clinically interpretable disease genes using only 
human phenotype information rather than model organism phenotype data, the analysis of 
sequencing results for previously reported mutations in ClinVar and the public version of 
HGMD, and the use of prioritization based on the modes of inheritance of diseases 
associated with candidate genes compared with the distribution of sequenced variants.  
Computational evaluation of PhenIX prioritization 
To test the performance of PhenIX prioritization with DAG panel sequencing, we used a 
simulation approach based on known disease-causing mutations from the Human Gene 
Mutation Database (HGMD). A total of 28,516 mutations were selected on the basis of being 
assigned as a disease-causing, single-nucleotide mutations (including indels) by HGMD and 
with HPO annotations available for the disease in question. For the simulations, 10,000 
variants were randomly selected from this set. We first removed the causative mutations 
from the 52 VCF files generated from the retrospective cohort with known mutations. Then, 
we added an additional mutation to one of these files. For autosomal dominant diseases, one 
heterozygous mutation was added; and for autosomal recessive diseases, either one 
homozygous mutation or two heterozygous mutations were added. The phenotypic (HPO) 
annotations for the corresponding disease were then compared to the HPO annotations 
associated with the 2741 disease genes (if a disease gene was associated with 
multiple diseases, all annotations were merged). There were three test scenarios. In 
the first case, all HPO annotations for the disease in question were used. In order to 
simulate incomplete phenotyping, we performed the simulations with up to five HPO 
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terms chosen at random from the annotations of the disease. Finally, in order to 
simulate the effects of noise, we randomly chose 2 or the 5 terms and promoted 
them to their less specific parent terms, and finally 2 new terms were chosen 
randomly from the whole of HPO and added to the annotations 
A rank was determined for the original disease gene following PhenIX analysis. In all 
the analysis, an ordinal ranking method was used in which equal scoring genes are 
resolved arbitrarily but consistently by assigning a unique rank to each of the ties. In our 
case, we simply sorted the equally scored genes alphabetically and assign the ranks. We 
recorded the number of times the correct disease gene was ranked in first place, as well as 
the total recall (correct gene listed at any rank). For each simulation, one of the 52 DAG 
panel VCF files was chosen.  
 
Clinical evaluation and validation of NGS results 
We clinically evaluated the NGS results using the PhenIX server, which implements the 
algorithm described above.  PhenIX presents a ranked gene list together with links to various 
other resources such as the UCSC browser (52), Entrez Gene (53), OMIM (1), Orphanet (2), 
ClinVar (41), MutationTaster (16), and HGMD (39). Evaluation was performed by trained 
genetics professionals. For each unsolved case, the top 20 ranked candidates were 
examined by comparison with the above mentioned data sources and as appropriate with the 
original literature. An initial assessment of these 20 candidates was possible in about two 
hours, and resulted in a short list of candidates thought to be potential matches. These were 
discussed at clinical rounds by a team of clinicians and researchers including LM, TZ, LGM, 
SD, NE, MS, NCØ, MRS, UK, PK, PNR, SM, and DH. A consensus decision was reached on 
candidates to be validated by Sanger sequencing and cosegregation studies. We considered 
a case to be solved after clinical analysis and cosegregation studies if a degree of certainty 
was reached that led to reporting of the mutation and diagnosis in our clinical setting. 
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TABLES 
 
 
Mode of 
inheritance 
Genes Average 
rank 
AD ACVR1, ATL1, BRCA1, BRCA2, CHD7 (4), CLCN7, COL1A1, COL2A1, EXT1, FGFR2 (2), FGFR3, GDF5, KCNQ1, MLH1 (2), MLL2/KMT2D, MSH2, MSH6, MYBPC3, NF1 (6), P63, PTCH1, PTH1R (2), PTPN11 (2), SCN1A, SOS1, TRPS1, TSC1, WNT10A 
1.7  
AR ATM, ATP6V0A2, CLCN1 (2),  LRP5, PYCR1, SLC39A4 5 
X EFNB1, MECP2 (2), DMD, PHF6  1.8  
Table 1. 52 control patient cases with known mutations. The number of patients with a mutation in the given gene is indicated in parentheses.  
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Clinical presentation N 
Intellectual disability + multiple congenital anomalies (= more than 2 other organ systems 
affected) 
13 
Intellectual disability + other neuropsychological features 7 
Intellectual disability + musculoskeletal abnormalities 5 
Intellectual disability + eye abnormalities 1 
Intellectual disability + dysmorphic features 1 
Multiple congenital anomalies (more than 2 organ systems affected) without intellectual 
disability 
6 
Skeletal phenotype 5 
Eye and/or Ear phenotype 2 
 
Table 2. Summary of clinical signs and symptoms in 40 patients with unknown diagnosis 
 
 
  
 19 
 
 
ID Age, Sex Presentation Gene  Rank Diagnosis  MoI 
P1 3y (f) Intellectual disability + 
multiple congenital 
anomalies 
MLL 2 Wiedemann-Steiner 
syndrome (54)  
AD 
P2 5y (f) Intellectual disability + 
multiple congenital 
anomalies  
SYNGAP1 4 Mental retardation, MRD5 
(55)  
AD 
P3 6y (f) Skeletal phenotype FGFR2 1 Pfeiffer syndrome (56) 
 
AD 
P4 Death at 
5.5m (f) 
Multiple congenital 
anomalies without 
intellectual disability 
SH3PXD2B 6 Frank-ter Haar syndrome 
(57)  
AR 
P5 6m (f) Intellectual disability + 
neurological abnormalities
  
SLC6A3 1 Parkinsonism-dystonia (58)  AR 
P6 Fetus 
(m) Death 
at 22w of 
gestation 
Skeletal phenotype ALPL 2 Infantile hypophosphatasia 
(59) 
 
AR 
P7 7y 
(m) 
Eye phenotype NHS 2 Nance-Horan Syndrome / 
Cataract 40, X-linked (60)  
XR 
P8 14y (m) Intellectual disability + 
multiple congenital 
anomalies 
MLL  1 Wiedemann-Steiner 
syndrome (54) 
AD 
P9 6y (f) Intellectual disability + 
multiple congenital 
anomalies 
DYRK1A 4 Mental retardation, MRD7 
(61) 
AD 
P10 4 children 
between 1 
½ and 7y 
Intellectual disability + 
multiple congenital 
anomalies 
MCOLN1 1 Type IV mucolipidosis (62) AR 
P11 3y (m) Intellectual disability + 
multiple congenital 
anomalies 
RBM10 3 TARP syndrome (63) 
 
XR 
 
Table 3. Clinical category and final diagnosis of 11 patients whose diagnosis was identified 
by PhenIX analysis. Additional information, including complete lists of HPO terms used to 
describe the phenotypic abnormalities seen in these patients is available in Table S4. 
Patients P6 and P10 were referred from external centers. The “Rank” column shows the rank 
after PhenIX analysis before clinical evaluation. The average rank for all 11 cases was 2.5. 
MoI: mode of inheritance, AD: autosomal dominant, AR: autosomal recessive, XR: X-linked 
recessive. 
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FIGURE LEGENDS 
 
Fig.1. Computational evaluation of PhenIX. HGMD mutations were inserted into variant files 
from DAG panels from which the causative mutations had been removed and phenotypic 
annotations of the corresponding diseases were extracted from the HPO database. The 
genes were ranked using PhenIX. Results were simulated either on the entire disease set 
(All), or by filtering for known autosomal dominant (AD) or autosomal recessive (AR) 
diseases (see Figure S2). A total of 8504 (All), 3471 (AD), and 5006 (AR) simulations were 
performed. Data are shown as the percentage of simulations in which the correct genes was 
ranked in first place. Variant, only variant scores used to rank candidate genes. All terms, All 
HPO terms used to annotate a disease were used for PhenIX analysis. ≤5 terms, Up to 5 
HPO terms were chosen at random from the terms used to annotation the disease. ≤5 terms 
& noise, Up to 5 annotations are used, 2 of which are made imprecise by exchanging them 
with a more general parent term; additionally, two random “noise” terms were added. Results 
are shown for the correct gene being ranked as the single top hit, or being among the top 5, 
10, or 20 hits for the three test scenarios. 
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Fig 2. PhenIX workflow showing the clinical and bioinformatic analysis steps. After initial 
clinical evaluation, a decision is made to perform PhenIX analysis if no clinical diagnosis can 
be found. After sequencing and computational analysis, clinical evaluation of the top 20 gene 
candidates identifies genes for validation by Sanger sequencing and cosegregation studies. 
 
Figure S1. Distribution of the coverage fraction for all sequenced 96 samples. 
Figure S2.  Computational evaluation of PhenIX. 
Table S1. Percentage of target bases that exceed coverages of 10, 20, ..., 100 reads.  
Table S2. Read alignment and coverage summary statistics for the 96 DAG panels 
sequenced for this project (40 patients with unknown diagnosis P1-P40, 52 patients with 
known diagnosis C41-C92, 4 control samples R93-R96). 
Table S3. Average number of variants called only from the original BAM files from the DAG 
panels but not in simulated BAM files generated down-sampling reads to a typical exome 
coverage (100x). 
Table S4. Detailed clinical and molecular findings for the 11 individuals in whom a previously 
unknown diagnosis was clarified by PhenIX analysis.  HPO terms shown in bold match with 
the disease profiles in the HPO database for these diseases. 
Table S5. Clinical presentation of 29 patients for whom PhenIX analysis failed to reveal a 
molecular diagnosis. 
Table S6. List of genes (with references) present in the DAG panel. 
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